Search Result

Results for "

cAMP/PKA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PKA (42) Akt (1) Antibiotic (1) Apoptosis (4) Bacterial (1) Calcium Channel (1) CRFR (1) Epigenetic Reader Domain (1) ERK (1) Fluorescent Dye (1) Fungal (1) Myosin (3) NF-κB (1) p38 MAPK (1) Phosphodiesterase (PDE) (11) PKC (6) PPAR (1) Ras (2) ROCK (3)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Endocrinology (3) Infection (1) Inflammation/Immunology (9) Metabolic Disease (14) Neurological Disease (15)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: PKA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100530C

Sp-cAMPS sodium salt	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-100530B

Sp-cAMPS	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-110005

Sp-cAMPS triethylamine	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-B0764B

Bucladesine Dibutyryl cAMP; DBcAMP	PKA	Neurological Disease
Bucladesine (DBcAMP) is a membrane permeable selective activator that activates cyclic adenosine phosphate dependent protein kinase A (PKA). The main regulatory mechanism of Bucladesine involves the cAMP/PKA signaling pathway. When Bucladesine activates *PKA, it can promote a variety of cellular processes, including neurodevelopment, growth and plasticity. In particular, the cAMP/PKA* signaling pathway plays a key role in the expression of long-term enhancement (LTP) and long-term inhibition (LTD), as well as in the formation of long-term memory in the hippocampus. Bucladesine can be used to study memory formation and neuroplasticity .

HY-134308

*8-NBD-cAMP* sodium**	Fluorescent Dye	Others
8-NBD-cAMP sodium is a fluorescently labeled cyclic adenosine phosphate (cAMP) analogue. 8-NBD-cAMP sodium retains a similar biological activity to cAMP, regulating their activity by binding to specific proteins such as EPACs or *PKA. 8-NBD-cAMP* sodium can be used in fluorescent competitive binding experiments to evaluate the binding affinity of newly synthesized EPAC1 agonists to EPAC1 proteins .

HY-120994

Rp-8-CPT-cAMPS sodium	PKA	Neurological Disease Inflammation/Immunology
Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .

HY-120994A

Rp-8-CPT-cAMPS	PKA	Neurological Disease Inflammation/Immunology
Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .

HY-108047

MK-0873	Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .

HY-103322

6-Bnz-cAMP sodium salt

PKA Cancer

6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways .
HY-123396

8-Chloro-cAMP

PKA Cancer

8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity .

*6-Bnz-cAMP* sodium salt**	PKA	Cancer
6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways .

8-Chloro-cAMP	PKA	Cancer
8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent *PKA* activity. 8-Chloro-cAMP has anticancer activity .

HY-120994B

Sp-8-CPT-cAMPS	PKA	Neurological Disease Inflammation/Immunology
Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent *protein kinas A (PKA* I and PKA II)*. Sp-8-CPT-cAMPS* selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .

HY-100530A

Rp-cAMPS	PKA	Neurological Disease
Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .

HY-100530D

Rp-cAMPS sodium salt 3 Publications Verification	PKA	Neurological Disease
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .

HY-P0248

Kemptide

PKA Metabolic Disease

Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).

Kemptide	PKA	Metabolic Disease
Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).

HY-100530

Rp-cAMPS triethylammonium salt	PKA	Neurological Disease
Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .

HY-B0764A

Bucladesine calcium Maximum Cited Publications 25 Publications Verification Dibutyryl cAMP calcium salt; DBcAMP calcium salt	PKA Phosphodiesterase (PDE) Apoptosis	Others
Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 2 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-P1290

PKA Inhibitor Fragment (6-22) amide PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .

HY-P3930

PKI (5-24),amide IP20-amide	PKA	Neurological Disease
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a K_i of 2.3 nM .

HY-12306

*8-Bromo-cAMP* sodium salt** 15+ Cited Publications 8-Br-cAMP sodium salt	PKA Apoptosis	Cancer
8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .

HY-12306A

8-Bromo-cAMP 15+ Cited Publications 8-Br-cAMP	PKA Apoptosis	Cancer
8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .

HY-P0291

Kemptide Phospho-Ser5

PKA Others

Kemptide (Phospho-Ser5) is a phosphate acceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA).
HY-P3770

Phosphate acceptor peptide

PKC Others

Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .

Kemptide Phospho-Ser5	PKA	Others
Kemptide (Phospho-Ser5) is a phosphate acceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA).

Phosphate acceptor peptide	PKC	Others
Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .

HY-B0764

Bucladesine sodium Maximum Cited Publications 25 Publications Verification Dibutyryl cAMP sodium salt; DBcAMP sodium salt	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective *PKA* activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .

HY-137640A

Sp-8-Br-cAMPS sodium	PKA	Inflammation/Immunology
Sp-8-Br-cAMPS sodium is a cAMP analog, which performs a protein kinase A (PKA) activating activity with EC₅₀ of 360 nM. Sp-8-Br-cAMPS sodium inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .

HY-B1898

Metadoxine	PKA	Metabolic Disease
Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein *(PKA-CREB)* pathway.

HY-P1595

CREBtide	PKA	Metabolic Disease
CREBtide is a CREB (cAMP response element binding protein)-like peptide. CREBtide, a synthetic 13 amino acid peptide, has been reported as a *PKA* substrate.

HY-B0764R

Bucladesine sodium (Standard)	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
Bucladesine (sodium) (Standard) is the analytical standard of Bucladesine (sodium). This product is intended for research and analytical applications. Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective *PKA* activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .

HY-136172

ESI-08	Ras	Cardiovascular Disease Metabolic Disease Cancer
ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC₅₀ of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation .

HY-P1291

PKI 14-22 amide,myristoylated	PKA	Cancer
PKI 14-22 amide,myristoylated is a potent **cAMP-dependent PKA** inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .

HY-P1595A

CREBtide TFA	PKA	Metabolic Disease
CREBtide TFA is a CREB (cAMP response element binding protein)-like peptide. CREBtide TFA a synthetic 13 amino acid peptide, has been reported as a *PKA* substrate .

HY-P1291A

PKI 14-22 amide,myristoylated TFA	PKA	Cancer
PKI 14-22 amide,myristoylated TFA is a potent **cAMP-dependent PKA** inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .

HY-107543

*8-CPT-2Me-cAMP* sodium**	Ras	Others
8-CPT-2Me-cAMP sodium is a selective activator of *exchange proteins activated by cAMP* (Epac)*, the cAMP* sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀> 10 μM) . 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro .

HY-110218

CW 008	PKA Epigenetic Reader Domain	Others
CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .

HY-107544

*8-pCPT-2'-O-Me-cAMP-AM*	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with *PKA* pathway .

HY-P1597

Malantide	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m** of 16 μM .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a K_m** of 16 μM .

HY-N3464

Isopedicin	Phosphodiesterase (PDE)	Metabolic Disease
Isopedicin potently and concentration-dependently inhibits superoxide anion (O2 U?) production in formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-activated cells. Isopedicin increases cAMP formation and PKA activity in FMLP-activated cells by inhibiting phosphodiesterase (PDE) activity .

HY-P0222

PKI(5-24) 3 Publications Verification	PKA	Others
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P0222A

PKI(5-24) TFA	PKA	Others
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-148827A

GEM-231 sodium HYBO-165 sodium	PKA	Cancer
GEM231 sodium is an 18mer antisense oligonucleotide targeting the mRNA of the *PKA-I* (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 sodium induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.

HY-148827

GEM-231 HYBO-165	PKA	Cancer
GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the *PKA-I* (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.

HY-100984

HA-100 1 Publications Verification	PKA PKC Myosin ROCK	Cancer
HA-100 is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), **cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK** inhibitor .

HY-100984A

HA-100 hydrochloride	PKA PKC Myosin ROCK	Cancer
HA-100 hydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor .

HY-12880

HA-100 dihydrochloride	Myosin PKA PKC ROCK	Cancer
HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor .

HY-108618

BC11-38	Phosphodiesterase (PDE)	Endocrinology
BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC₅₀s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells .

HY-Q40876

BBT	Calcium Channel	Metabolic Disease
BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ)-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .

HY-128358

MR-L2	Phosphodiesterase (PDE)	Neurological Disease
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC₅₀ of 1.2 µM .

HY-N2118

Bilobetin 1 Publications Verification	PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and *PKA* activity .

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor with K_i values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

Cat. No.	Product Name	Target	Research Area

HY-P0248

Kemptide

PKA Metabolic Disease

Kemptide is a synthetic heptapeptide that acts as a specific substrate for cAMP-dependent protein kinase (PKA).

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 2 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-P1290

PKA Inhibitor Fragment (6-22) amide PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide can significantly reverse low-level morphine antinociceptive tolerance in mice .

HY-P3930

PKI (5-24),amide IP20-amide	PKA	Neurological Disease
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a K_i of 2.3 nM .

HY-P0291

Kemptide Phospho-Ser5

PKA Others

Kemptide (Phospho-Ser5) is a phosphate acceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA).
HY-P3770

Phosphate acceptor peptide

PKC Others

Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .

HY-P1595

CREBtide	PKA	Metabolic Disease
CREBtide is a CREB (cAMP response element binding protein)-like peptide. CREBtide, a synthetic 13 amino acid peptide, has been reported as a *PKA* substrate.

HY-P1291

PKI 14-22 amide,myristoylated	PKA	Cancer
PKI 14-22 amide,myristoylated is a potent **cAMP-dependent PKA** inhibitor. PKI 14-22 amide,myristoylated reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .

HY-P1595A

CREBtide TFA	PKA	Metabolic Disease
CREBtide TFA is a CREB (cAMP response element binding protein)-like peptide. CREBtide TFA a synthetic 13 amino acid peptide, has been reported as a *PKA* substrate .

HY-P1291A

PKI 14-22 amide,myristoylated TFA	PKA	Cancer
PKI 14-22 amide,myristoylated TFA is a potent **cAMP-dependent PKA** inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion .

HY-P1597

Malantide	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m** of 16 μM .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by **cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a K_m** of 16 μM .

HY-P10336

Serpinin	Peptides	Neurological Disease Endocrinology
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .

HY-P0222

PKI(5-24) 3 Publications Verification	PKA	Others
PKI(5-24) is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P0222A

PKI(5-24) TFA	PKA	Others
PKI(5-24) TFA is a potent, competitive, and synthetic peptide inhibitor of *PKA* (cAMP-dependent protein kinase), with a K_i of 2.3 nM. PKI(5-24) TFA corresponds to residues 5-24 in the naturally occurring heat-stable protein kinase inhibitor .

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor with K_i values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

Species:	Human (3) Canine (1)
Tag:	His (1) Tag Free (2) GST (1)
Source:	Sf9 insect cells (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P701068

PKA/PRKACA Protein, Canine (His)

cAMP-dependent protein; PRKACA; PKA C-alpha; PKACA; PKA C alpha; PPNAD4
Canine E. coli

HY-P701753

	PKACα Protein, Human (Sf9, GST) PRKACA; cAMP-dependent protein kinase catalytic subunit alpha; PKA C-alpha	Human	Sf9 insect cells
	PKACα protein is a key kinase that phosphorylates a variety of substrates, including CDC25B, ABL1, NFKB1, and VASP, affecting a variety of cellular processes, such as cell cycle progression, platelet regulation, and adipogenic differentiation. It also negatively regulates mTORC1 through RPTOR phosphorylation, thereby modulating signaling networks. PKACα Protein, Human (Sf9, GST) is the recombinant human-derived PKACα protein, expressed by Sf9 insect cells , with GST tagged. The total length of PKACα Protein, Human (Sf9, GST) is 350 a.a., .

HY-P702638

	PRKACG Protein, Human (sf9) PRKACG; protein kinase, cAMP-dependent, catalytic, gamma; cAMP-dependent protein kinase catalytic subunit gamma; PKACg; PKA C-gamma; serine(threonine) protein kinase; KAPG	Human	Sf9 insect cells

HY-P702637

	PRKACB Protein, Human (sf9) PRKACB; protein kinase, cAMP-dependent, catalytic, beta; cAMP-dependent protein kinase catalytic subunit beta; PKACb; PKA C-beta; protein kinase A catalytic subunit beta; cAMP-dependent protein kinase catalytic beta subunit isoform 4ab; PKACB; MGC9320; MGC41879; DKFZp781I2452	Human	Sf9 insect cells

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81127

	PKA alpha + beta Antibody PRKACA/PRKACB; PRKACA + PRKACB; PKA alpha + beta; PKA alpha; PKA beta; cAMP dependent protein kinase alpha catalytic subunit; cAMP dependent protein kinase beta catalytic subunit; cAMP dependent protein kinase catalytic subunit alpha; cAMP dependent protein kinase catalytic subunit beta; DKFZp781I2452; MGC102831; MGC41879; MGC48865; MGC9320; PKA C alpha; PKA C beta; PKACA; PKACB; PRKACA; PRKACB; Protein kinase A catalytic subunit alpha; Protein kinase A catalytic subunit; Protein kinase A catalytic subunit beta; Protein kinase cAMP dependent catalytic alpha; Protein kinase cAMP dependent catalytic beta; cAMP dependent protein kinase catalytic subunit alpha isoform 1; cAMP-dependent protein kinase catalytic subunit alpha; KAPCA_HUMAN; KAPCB_HUMAN; PKA C alpha; PKA C-alpha; PKACA; PRKACA; Protein kinase A catalytic subunit; Protein kinase cAMP dependent catalytic alpha.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse
	PKA alpha + beta Antibody is an unconjugated, approximately 40 kDa, rabbit-derived, anti-PKA alpha + beta polyclonal antibody. PKA alpha + beta Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, and predicted: rat background without labeling.

HY-P81981

	PKA C gamma Antibody (YA1726) PRKACG; cAMP-dependent protein kinase catalytic subunit gamma; PKA C-gamma	WB, IP	Human, Mouse, Rat
	PKA C gamma Antibody (YA1726) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1726), targeting PKA C gamma, with a predicted molecular weight of 40 kDa (observed band size: 40 kDa). PKA C gamma Antibody (YA1726) can be used for WB, IP experiment in human, mouse, rat background.

HY-P80847

	Phospho-PKA RII alpha (Ser99) Antibody PRKAR2A; PKR2; PRKAR2; cAMP-dependent protein kinase type II-alpha regulatory subunit	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Pig
	Phospho-PKA RII alpha (Ser99) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 46 kDa, targeting to Phospho-PKA RII alpha (Ser99). It can be used for WB,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Pig.

HY-P82006

	PKA RI alpha Antibody (YA1751) PRKAR1A; PKR1; PRKAR1; TSE1; cAMP-dependent protein kinase type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1	WB	Human, Rat
	PKA RI alpha Antibody (YA1751) is a biotin-conjugated non-conjugated IgG antibody, targeting PKA RI alpha, with a predicted molecular weight of 43 kDa (observed band size: 43 kDa). PKA RI alpha Antibody (YA1751) can be used for WB experiment in human, rat background.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

cAMP/PKA

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products